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Introduction
Ovarian cancer is one of the most common of all gynecologic 
malignancies and represents one of the leading causes of 
cancer death for women. The disease has become a major 
health problem because of the increasing incidence rate 
every year.1,2 In 2012 GLOBOCAN estimated that 239 000 
women were diagnosed with ovarian cancer with 152 000 
women deaths worldwide annually, and some 600 000 
women were living within five years of a diagnosis. 
The incidence steadily has increased, and in 2015 there 
were 251 000 new cases with about 161 000 women who 
died from the disease.1,3 Surgical resection of the tumor 
followed by platinum and texane based chemotherapy 
are the primary therapeutic interventions. Although 
the majority of patients respond to initial treatment, the 
5-year survival rate remains only 30%. The condition is 
typically associated with more aggressive tumors, massive 
peritoneal dissemination and resistance.4,5 
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Abstract
Purpose: Ovarian cancer is the most lethal of gynecological malignancies. Recently, the 
development of microRNA (miRNA) -based therapeutics that could impact broad cellular 
programs, leading to inhibition of cancer cell viability, is gaining attention in the therapeutic 
landscape. The therapy is based on the presence of aberrant expressions of miRNA in cancer 
cells. Decreasing of tumor suppressor miRNA expression causes upregulation of oncoprotein, 
which worsens the prognosis of the ovarian cancer. 
Methods: miR-155-5p mimics were carried by chitosan nanoparticles using new nanotechnology 
methods. Cellular uptake of miRNA was assessed by fluorescence microscope while MTT and 
qPCR assay were used to determine miRNA profile and the effect of CS-NP/miRNA on SKOV3 
cells.
Results: Results of profiling validated using quantitative realtime-polymerase chain reaction 
(PCR) found one of the most altered tumor suppressor miRNAs, miR-155-5p was downregulated 
892.15-fold. According to bioinformatic analysis we identified the miRNA could recognize 
and regulate HIF1α expression. Transfection of mimics for miR-155-5p showed significantly 
increased miR-155-5p endogen SKOV3 expression level compared to the control group. We 
found differences after transfection mimics for miR-155-5p 31.5 and 63 nanoMolar. Increasing 
of miR-155-5p endogen lead to diminished SKOV3 viability (by 30%; <0.05 at concentration 
80 nanoMolar). These mimics may cause an increase in upregulated miR-155-5p endogen that 
can reduce HIF1α expression. Here we found 2-fold and 2.8-fold reduction of HIF1α expression 
level after transfection compared to the control group. 
Conclusion: According to these findings, the mimics miR-155-5p can inhibit ovarian cancer cell 
proliferation by regulating HIF1α expression.
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Recently researchers found that microRNAs (miRNAs), 
an emerging class of small non-coding RNAs are 
implicated in a wide variety of cellular processes including 
ovarian cancer. The worsening prognosis of this disease 
is also found to be related to miRNA expression patterns. 
MiRNAs are small non-coding RNA molecules (18-24 nt) 
that play roles in the regulation of target-gene expression 
post-transcriptionally by binding to complementary 
target mRNAs which results in mRNA translational 
inhibition or degradation.6,7 They have been widely 
implicated in pathogenesis of several human diseases, 
including cancers.8 Their aberrant expression in tumors 
have important pathogenetic consequences. MiRNAs that 
are overexpressed in tumors contribute to oncogenesis 
by downregulating tumor suppressors, while the tumor 
suppressor miRNAs that contribute to oncogenesis 
by downregulating oncogenic protein expression are 
downregulated. Recent studies found that one miRNA can 
regulate hundreds of target genes and play a role in global 
cellular physiology.9,10
For example, miRNA-21 is an oncomirRNA that can 
repress expression of tumor suppressor protein PDCD4 
in colorectal cancer by recognizing and interacting with 
3’UTR of messenger RNA.11 Another miRNA that becomes 
upregulated is miR 210 which modulates the expression 
of proteins involved with SHDH, a tumor suppressor that 
has a role in HIF1α expression and causes lung cancer 
cell survival.12 Binding of miR-10b in HOXD10 mRNA 
also initiates gene translation repression and leads to 
metastasis of breast and ovarian cancer.13,14 
Contrarily, another important set of miRNAs that is 
downregulated in cancer is the tumor suppressor miRNAs 
that play roles in the repression of oncogenic protein 
translation.9 Decrease of these protein levels leads to cancer 
progression. For example, deletions of chromosomal loci in 
chronic lymphocytic leukemia lead to downregulation of 
tumor suppressor miRNAs, miR-15 and miR-16. They are 
important in chronic lymphocytic leukemia by targeting 
Bcl-2 mRNA and decreasing of their expression results in 
the development of an autonomous lymphoproliferative 
disorder.15,16 Another tumor suppressor miRNA that has 
received substantial attention is miR-34 which is involved 
in tumor cell cycle by regulation of CDK4 and CDK6 
expressions, and also metastasis proteins such as MET, 
Notch, MYC and AXL expression.17 
The importance of the role of miRNA in cancer is 
becoming more understood, and it is possible to be 
used as a therapeutic approach through the use of anti-
miR which will modulate the oncogenic inhibition of 
miRNA and mimic miRNA to help endogenous miRNA 
suppress tumors by suppressing the oncogenic expression 
of proteins.18,19 Both of these therapeutic approaches 
have been shown to be effective in vitro and in vivo for 
several types of cancers such as prostate, breast, and 
colorectal cancer.18-20 Due to the nature of miRNA that is 
easily degraded in blood circulation and the difficulty in 
achieving its target when given systemically in the form 
of naked miRNA, it needs an appropriate vector.7 The 
strategy developed in the delivery of the miRNA to the 
site of action is by formulating it in nano-sized carriers. 
Nanoparticles are non-viral vectors which are often used 
in conveying genetic material because they are relatively 
safe to use and are able to protect the miRNA from 
nucleation degradation and deliver it into the intracellular 
compartment of the target cell.21,22 Chitosan is a cationic 
polymer that is often formulated as an oligonucleotide 
nanocarrier because it forms nano-sized and stable 
particles and forms complexes with oligonucleotides 
to carry them through cell membranes or tissues.21,23,24 
Therefore, chitosan is considered capable of being used as 
a nanocarrier for the delivery of miRNA into cancer cells.
The purpose of this study was to characterize and 
evaluate the effect of chitosan nanoparticles miRNA-155-
5p in alleviating ovarian cancer cell lines of SKOV3.
Materials and Methods
Materials 
The human epithelial ovarian cancer cell lines SKOV3 
and Vero (normal cell line) were obtained from Stem 
Cell and Cancer Institute Kalbe (Jakarta, Indonesia). 
Ovarian cancer cell lines were grown in DMEM High 
Glucose (Massachusetts, USA) supplemented with 10% 
fetal bovine qualified serum (Massachusetts, USA), 1% 
Penicillin-Streptomycin (Massachusetts, USA), and 0.5% 
amphotericin (Massachusetts, USA). Exiqon miRCURY 
LNATM Universal RT microRNA PCR kit, miRCURY 
RNA Cell and Plant Kit, Universal cDNA synthesis kit II 
8-64 rxns were purchased from Exiqon (Woburn, USA). 
Chitosan medium molecular weight were purchased from 
Sigma Aldrich (St. Louis, MO). 
 
Determination of miR-155-5p levels of normal and 
ovarian cancer cell lines by qRT-PCR
To determine the miRNA expression profiles of ovarian 
cancer cell line (SKOV3) and Vero cell line (normal), 
we used quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR) in two panels of sample cells. 
The Exiqon miRCURY LNATM Universal RT microRNA 
PCR kit was used for all experiments. The procedure 
was conducted according to the manufacturer’s protocol. 
The miRNA expression was measured with Biorad CFX 
96. Results of measurement were analysis by Biorad CFX 
ManagerTM and GENEX software.
Chitosan nanoparticle-miRNA preparation
The nanoparticle formulation begins by dissolving the 
chitosan medium molecular weight powder into 1% acetic 
acid and stirring for 4 hours (with a magnetic stirrer). 
After adjusting pH with 1 M NaOH to pH 5.5, then the 
solution was regenerated with acetate buffer pH 5 so that 
0.2% chitosan solution was obtained. Nanoparticles were 
made by ionic gelation method by mixing 0.2% chitosan 
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with sodium tripolyphosphate (5:1) and incubating for 5 
minutes at room temperature. 150 μL of the solution was 
conjugated with 150 μL of mimic miR-155-5p and then 
incubated for 20 minutes at room temperature.
Efficiency entrapment
Efficiency entrapment of hsa-miR-155-5p microRNA 
encapsulation by chitosan nanoparticles was done by 
measuring the free concentration of hsa-miR-155-5p/
antimiR-324-5p in the formula. Prepared nanoparticles 
were centrifuged for 15 minutes at a speed of 13,000 g. 
The supernatant obtained was measured by its absorbance 
using NANO-Quant (SPARK TECAN). Its absorption 
efficiency (%) was obtained from the percentage of 
encapsulated microRNAs (total miRNA-free miRNA) 
compared to the total RNA.
In vitro cellular uptake
SKOV3 lines were seeded in 24 well plates at a density of 4 
×104/well with borosilicate coated covered glass, followed 
by incubation. After 24-hours incubation, cells were 
transfected with chitosan nano-particle/FAM-conjugated 
miRNA-155-5p complexes with a concentration of 
miRNA 2 μM. Cellular uptake of miRNA was assessed 
by fluorescence microscopy (Carl Zeiss Axio®) 4 hours 
post incubation with miRNA labeled FAM. Prior to 
observation, cells were washed with DPBS to disperse the 
nanoparticles and then the cells were stained by DAPI to 
visualize nuclei.
Cell viability assay
Cytotoxic tests were conducted by MTT Assay method 
using SKOV3 line cells. SKOV3 line cells (6000/well) 
were grown on a 96-well plate and incubated for 24 hours 
at 37°C and 5% CO2. The media was removed from the 
well plate, and the prepared nanoparticles (mixed with 
serum DMEM Free media) were put into the well (100 μL/
well) then incubated for 24 hours at 37°C and 5% CO2. 
The test solution was removed and the well-plate was 
filled with 100 μL MTT 0.5 mg/mL. After incubation for 
4 hours, 100 μL stop solution (SDS 10%, and 0.01 mol/L 
HCl) were added to dissolve formazan crystals and then 
were incubated again for 18 hours at room temperature 
in the absence of light. The absorbance of each well was 
measured at a 595 nm wavelength using a Micro Plate 
Reader (Bio-Rad Model 680 XR).
Gene target prediction 
Gene target prediction was assessed to predict the 
complementary binding of microRNA-mRNA using 
starmiRDB and GeneCard. 
Total RNA was isolated by miRCURY RNA Cell 
and Plant Kit, according to the manual protocol. RNA 
concentration was measured by a nanodrop at wavelengths 
of 260 and 280 nm. 10 ng of the total RNA in reverse 
transcription becomes cDNA according to the protocol kit 
used, namely Universal cDNA synthesis kit II 8-64 rxns. 
Quantification of miRNA-155-5p (5’-UUAAUGCUAAUC 
GUGAUAGGGGU-3’) was done using the ExiLent SYBR 
Green master mix kit, 2.5 mL (Cat No. 203402, Exiqon). 
miRNA-16-5p (5’-UAGCAGCACGUAAAUAUUGG CG-
3’) was used as housekeeping gene.
Meanwhile, quantification of HIF1α mRNA expression 
used the following primers: (forward: 5’-AATGCTC 
CCCTCACCCAACG-3’; reverse 5’-GCAGGGTCAG 
CACTACTTCG-3) using SensiFASTTM SYBR® kit 
(Cat. No. BIO-98020, Bioline) and β-actin (forward: 
5’GGGAATTCAAAACTGGAACGGTGAAGG3’; reverse 
5’GGAA GCTTATCAAAGTCCTCGGCCA CA-3 ‘) was 
employed as housekeeping gene. All gene transcriptions 
were quantified using the Biorad CFX 96 C.1000 
quantitative PCR machine. Relative gene expressions 
were analyzed using the 2-ΔΔCT method by Bio-Rad CFX 
Manager 3.0 and GenEx software version 6.1 and the 
results were expressed as the fold change.
Statistical analysis
All measurements were done in triplicate and expressed 
as mean ± standard deviation (SD). Statistical analyses 
of miR-155-5p and HIF1α expression were performed 
using one-way ANOVA and to determine the presence of 
any significant differences between groups, followed by 
Bonferroni tests. All the data were analyzed using SPSS 
16 software (SPSS Inc., Chicago, USA) and graphics were 
performed by GraphPad Prism 7. Statistical significance 
was set at P < 0.05. 
Results and Discussion
Profile expression of miRNAs in ovarian cancer cell 
Recently, the use of miRNA-based therapies as an approach 
in the treatment of diseases such as cancer and infections 
has been gaining attention. Aberrant expression of 
miRNA in ovarian cancer causes worsening prognosis of 
the cancer. This therapy aims to suppress the expression of 
oncogenic proteins by inserting mimic oligonucleotides.10
In this study, we determined there were many miRNA 
levels which were expressed showing differences between 
ovarian cancer cell line SKOV3 compared to normal cell 
line. We analyzed about 60 miRNAs from both of the 
SKOV3 and Vero cell lines that dysregulated (upregulated 
and downregulated). Of the 60 miRNAs, we found that 
miRNA-155-5p was the most common miRNA that 
appeared to be dysregulated (downregulated) about 
892.15 times compared to the normal cell line (P < 0.05).
MiRNA 155 is a multifunctional microRNA located on 
chromosome 21q21.3 and involved in various biological 
and pathological processes in the body when it is 
disregulated.25 In ovarian cancer, this miRNA belongs 
to a group of tumor suppressor miRNAs that are able to 
regulate the regulation of the expression of some oncogenic 
proteins such as claudin-1 (CLDN1) which is important 
for the invasion and adhesion of ovarian cancer-initiating 
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cells.26 In addition, this miRNA can directly recognize and 
inhibit XIAP expression and promote apoptosis in ovarian 
cancer cells SKOV3, A2780, and primary cultured ovarian 
cancer cells. Furthermore, the administration of miR-
155-5p expression on ovarian cancer cells can increase 
the sensitivity of cisplatin to ovarian cancer cells.25 
Downregulation of its expression causes the ability to 
carry out its duties in suppressing protein oncogenesis to 
be reduced and causes worsening prognosis of the cancer.
Evaluation of miRNA-155-5p transfection by chitosan 
nanoparticle
To further show transfection efficiency was investigated 
by FAM detection of fluorescence microscopy (Carl Zeiss 
Axio®) and miR-155-5p expression level by qPCR. As seen 
from the arrows in Figure 1, green fluorescence of FAM 
labelled miR-155-5p were detected at 4 h post-incubation 
in cytoplasmic of SKOV3 cell, while the naked miR-155-
5p had no fluorescence after 4 h post-incubation.
According to previous cellular uptake study by chitosan/
FAM mimic miR-155-5p and antimiR-324-5p found 
that release miRNA might occur within the first 4 h for 
most of the tested chitosans. Furthermore, to access the 
uptake cellular of mimic miR-155-5p, we also measured 
endogenous miR-155-5p level by qPCR (Figure 2).
Efficiency entrapment
The encapsulation efficiency of microRNA by chitosan 
can be seen in Figure 3. The efficiency of encapsulation in 
nanoparticles is very important in the therapeutic effect 
of microRNA delivered using a nanocarrier system. This 
efficiency value refers to the amount of microRNA that is 
absorbed in the chitosan matrix through two mechanisms 
namely the ionic interaction of the (-NH3+) group with 
a negative charge of miRNA and tripolyphosphate of 
crosslinker. In the figure it appears that 57.43% of miRNA-
155-5p is absorbed in the nanochitosan. This entrapment 
efficiency is influenced by chitosan concentration. The 
low concentration of chitosan will result in a low chitosan 
viscosity which also causes the miRNA to penetrate more 
quickly into the polymer matrix.27
The absorption of microRNAs in this chitosan matrix 
enables miRNA-155-5p protection from the degradation 
of the nuclear enzyme and is easily delivered to the target 
action to carry out its function in silencing the expression 
of target genes and initiating inhibition of ovarian cancer 
cell proliferation. This is evidenced by the presence of 
microRNA luminescence labeled FAM (green) in the 
cytoplasmic region of SKOV3 cells (Figure 2). This 
luminescence was not found in groups of cells that were 
transfected without chitosan. Besides this finding, it is 
also proven by the results of cytotoxic test between miR-
155-5p expression without and encapsulated chitosan in 
Figure 4. In the figure, it appears that the administration of 
mimic miRNA without conjugated miRNA does not have 
an inhibitory effect on ovarian cancer cell proliferation 
compared to the mimic miRNA that was conjugated with 
nanoparticles chitosan (Figure 4).
Effect of miRNA-155-5p on viability of SKOV3 cell 
Cell viability study of nanoplexes were conducted 
using the mitochondrial dehydrogenase performance 
measurement, also known as the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (methyl 
Figure. 1 Differentially expressed miRNAs. a. heat-map representation of expression patterns of the differentially expressed miRNAs in ovarian cancer cell line versus 
Vero cell line. Rows of the heat map represent miRNAs; columns show profiled cancer and the control (normal) group comprises Vero cell line. Relative expression is 
represented as a colorgram (Blue: high expression). b. The expression of miRNAs as determined by qPCR analysis. Shown are comparisons of the average relative expres-
sion levels of hsa-miR-155-5p in ovarian cancer cell line and Vero cell line (P < 0.05).
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thiazolyl tetra-zolium; MTT) assay (Figure 4). Our 
findings show significant inhibition on cell viability 
after treated by mimic miR-155-5p compared to control 
(P < 0.05).
MTT assay is a colorimetric method in cytotoxicity test 
that is used because it is simple. This method is based on 
mitochondrial dehydrogenase activity in cytochrome b 
and c from living SKOV3 cells that can cut the tetrazole 
ring of MTT and are reduced to form purple formazan 
crystals. This substance is easily dissolved in dimethyl 
sulfoxide or other organic impurities.28 The assay was 
done with several variations of the concentration of 
mimic oligonucleotide and anti-miRNA namely 30 nM, 
40 nM, 50 nM 60 nM 70 nM and 80 nM. This increased 
percentage of inhibition of cell death was not seen in the 
treatment group given microRNA without chitosan.
This finding is likely due to the administered microRNA 
Figure. 2 Cellular uptake localization of chitosan/FAM-miR-155-5p mimic 
nanoplexes in SKOV3 cell lines after 4 h incubation by fluorescence mi-
croscopy.
Figure 3. The efficiency of the mimic miR-155-5p encapsuled in chitosan 
nanoparticles measured by NANO-Quant (SPARK TECAN).
Figure 4. Inhibition Proliferation of chitosan nanoparticle of mimic miR-155-
5p to ovarian cancer cell line SKOV3 (n=3). The persentage are mean ± SD. 
*P < 0.05 and **P < 0.005 versus naked mimic miR-155-p. Abbreviations: 
Ch-NPs, chitosan nanoparticles.
being degraded before reaching the target action so that it 
cannot carry out its function in suppressing the expression 
of the target gene. Inhibition of cell growth in the test 
group treated with miRNA chitosan nanoparticles is an 
indication that the microRNA has successfully entered 
the SKOV3 cell and performs its function in suppressing 
the expression of target genes (e.g XIAP and CLDN1) and 
initiating cancer cell death.
In silico miRNA target prediction
Furthermore, our bioinformatics analysis found that 
miRNA-155-5p that acts as a tumor suppressor miRNA 
in ovarian cancer can recognize HIF1α at 2655-2669 base 
with logistic probability of 0.854 and ΔGtotal -13.39 kcal/
mol (Figure 5).
Effect of mimic miRNA-155-5p on endogenous miRNA-
155-5p and HIF1α expression level on SKOV3
To assess whether the nanoparticles were able to deliver 
mimic miRNA-155-5p in a functional location on 
SKOV3, we measured the miR-155-5p level after 24-
hour incubation by qPCR and compared the results 
with the control cells. As seen in Figure 6A, there were 
significant differences of miRNA-155-5p level between 
the control and chitosan nanoparticle miR-155-5p in 
both of the 31.5 nM and 63 nm groups in the SKOV3 cell 
line. Furthermore, we confirmed that transfected mimic 
miRNAs were functional miRNA by measuring the target 
of miRNA, such as HIF1α mRNA expression as the one of 
the miR-155-5p direct targets as shown in Figure 6B. 
Furthermore, we found that expression levels of miR-
155-5p were significantly upregulated after 24-hour 
transfection of chitosan nanoparticle mimic miRNA-155-
5p (P < 0.05) (Figure 5A). Increasing of level endogenous 
miR-155-5p SKOV3 lead to poor viability of SKOV3 cell 
line (Figure 4). Assess of miRNA level does not accurately 
report the level of functional miRNA transfected because 
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it does not distinguish between miRNAs in functional 
or non-functional pools. To assess that the transfected 
miRNAs are functional, we evaluated the biological 
effects of miRNA-155-5p on silencing the target gene. As 
seen from in silico analysis results miR-155-5p is a tumor 
suppressor miRNA that can recognize and interact with 
oncogenic post transcription gene HIF1α. Furthermore, to 
confirm that entered mimic miRNAs have biology effect, 
we measured the HIF1α mRNA expression.29 Previously a 
negative correlation was reported between miRNA-155-
5p expression level and mRNA HIF1α in ovarian cancer 
serum.
According to Zhu et al HIF1α was expressed in SKOV3 
cell line. In this study, we found that increasing of miR-
155-5p levels can reduce HIF1α expression level.30 The 
decrease of HIF1α levels are statistically significant to 
control group vs 31.5 nM and 63 nM treatment group. 
This is consistent with the findings of Bruning et al that 
showed application of miR-155 can reduce the expression 
of HIF-1α mRNA, protein and transcriptional activity in 
hypoxia.31
Hypoxia-inducible factor 1-alpha is a master regulator of 
oxygen homeostasis by inducing glycolysis, erythropoiesis, 
and angiogenesis. The protein is commonly upregulated 
in human cancers as survival mechanism and in their 
metastases. The proteins demonstrated the ability to 
transcribe some oncogenic proteins such as VEGF, 
ABCB1 and GLUT-1 that play critical roles in the survival 
and metastasis of ovarian cancer cells.32
Conclusion
In summary, we concluded that chitosan nanoparticle 
could be used as a delivery system for anti and mimic 
miRNA. Furthermore, in vitro study revealed that miRNA 
transfection of mimic-155-5p that conjugated with 
chitosan nanoparticle can induce inhibition of viability of 
ovarian cancer cell line SKOV3 by decreasing HIF1α.
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Figure 5. In silico prediction of hsa-miRNA-155-5p-HIF1α-3′UTR recognition  and interaction is highly favorable and almost certain to occur in the cytoplasm 
/nucleoplasm of SKOV3 cells by  using computational tool StarMirDB combine with GeneCard. (a,c) hsa-miR-155-5 and HIF1α location in chromosome, (b) 
hsa-miRNA-155-5p-HIF1α-3′UTR interaction prediction.
Figure 6. Fold change of expression endogenous miRNA-155-5p (A) and mRNA HIF1α SKOV3 cell line post treathment NPs-CS mimics miRNA-155-5p 31,5 nM 
and 63 nM. Expression of miRNA and mRNA were measured by qPCR and analyzed using the 2-ΔΔCT method Fold change are mean ± SD *P < 0,05; **P < 0,01 
versus control group (SKOV3 cell line untreated).
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